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Abstract 
Background: Glioblastoma (GBM) is the deadliest of brain tumors. Standard treatment for GBM is surgery, followed 
by combined radiation therapy and chemotherapy. Current therapy prolongs survival but does not offer a cure. We 
report on a novel immunotherapy against GBM, tested in an animal model of C57BL/6 mice injected intra‑cranially 
with a lethal dose of murine GL261 glioma cells.
Methods: Ten week‑old C57BL/6 mice were anesthetized before injection of 2 × 104 GL261 cells in the right cerebral 
hemisphere and after 3 days half of the mice were administered a single subcutaneous (s.c.) injection of irradiated 
semi‑allogeneic vaccine, while mock‑vaccinated mice received a s.c. injection of phosphate‑buffered saline (PBS). 
Tumor engraftment was monitored through bioluminescence imaging (BLI). Length of animal survival was measured 
by Kaplan–Meier graphs and statistics. At time of sacrifice brain tissue was processed for estimation of tumor size and 
immunohistochemical studies.
Results: Overall survival of vaccinated mice was significantly longer compared to mock‑vaccinated mice. Five to 
ten percent of vaccinated mice survived more than 90 days following the engraftment of GL261 cells in the brain and 
appeared to be free of disease by BLI. Tumor volume in the brain of vaccinated mice was on average five to ten‑fold 
smaller compared to mock‑vaccinated mice. In vaccinated mice, conspicuous microglia infiltrates were observed in 
tumor tissue sections and activated microglia appeared to form a fence along the perimeter of the tumor cells. The 
results of these animal studies persuaded the Office of Orphan Products Development of the Food and Drug Admin‑
istration (FDA) to grant Orphan Drug Designation for treatment of GBM with irradiated, semi‑allogeneic vaccines.
Conclusions: Our preclinical observations suggest that semi‑allogeneic vaccines could be tested clinically on sub‑
jects with GBM, as an adjuvant to standard treatment.
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Background
Glioblastoma multiforme (GBM) is the deadliest of brain 
tumors and is one of a group of tumors referred to as 
gliomas. GBMs make up approximately 15  % of all pri-
mary brain tumors [1]. Classified as a Grade IV (most 
serious) astrocytoma, GBMs develop from the astro-
cytes that support nerve cells, primarily in the cerebral 
hemispheres, but can develop in other parts of the brain, 
brainstem, or spinal cord. Each year, more than 3000 
Americans are diagnosed with GBMs. The cure rate for 
GBMs is grim, with current therapy prolonging survival 
but not offering a cure.
Standard treatment for GBM is surgery, followed by 
combined radiation therapy and chemotherapy. GBM’s 
capacity to invade and infiltrate normal surrounding 
brain tissue makes complete resection virtually impossi-
ble. After surgery, combined chemo-radiation is used to 
kill residual tumor cells and to delay recurrence. Temo-
zolomide was approved by the Food and Drug Admin-
istration (FDA) in 2005 for treatment of adult GBM; 
subsequently, the FDA approved Avastin (Bevacizumab) 
for treating GBM. Nevertheless, with standard of care 
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with GBM is 15  months, and the 5-year survival rate is 
approximately 10 % [2]. This tumor ultimately takes the 
life of nearly every affected patient.
It has been recently reported that VA patients with 
GBM showed a decreased median survival (6.5 months) 
relative to a national cohort of adults (9.0 months); fur-
thermore, 1, 2, and 5 years survival rates in Veterans were 
26.8, 5.4, and 0.5  %, respectively, versus 37.8, 12.8, and 
4.1  %, respectively, in a comparable national cohort of 
adults. These GBM survival data highlight a potential dis-
parity and a much worse clinical outcome among affected 
Veterans [3]; therefore, it is important to explore addi-
tional therapeutic options for treating GBM, especially in 
Veterans.
The capacity of T cells to recognize allogeneic major 
histocompatibility complex (MHC) molecules as intact 
structures on the surface of foreign cells is called direct 
T cell allorecognition and is responsible for the power-
ful immune reactions associated with transplant rejec-
tion, a phenomenon called “alloagression” [4]. To a large 
extent this is due to the ability of allogeneic stimulation 
to mobilize up to 10  % of all T lymphocytes, compared 
with a precursor T-cell frequency of between 10−4 and 
10−5 for most common antigens. At the same time, each 
of the lymphocytes activated through direct allorecogni-
tion will also recognize specific antigenic peptides pre-
sented in the context of a self-MHC molecule (MHC 
restriction). Cross-reactivity between alloantigens and 
self MHC-restricted antigens can be harnessed to target 
tumor-associated antigens [4].
Experimental results from studies with inbred mice 
and their syngeneic tumors have indicated that the 
inoculation of semi-allogeneic cell hybrids (derived 
from the fusion between syngeneic tumor cells and an 
allogeneic cell line) protects the animal host from a sub-
sequent lethal inoculation with unmodified syngeneic 
tumor cells [5, 6]. Semi-allogeneic somatic cell hybrids 
were generated by fusing EL-4 T-lymphoma cells (H-2b) 
and BALB/c-derived renal adenocarcinoma RAG cells 
(H-2d); these hybrids were injected intra-peritoneally 
(i.p.) in C57BL/6 mice (H-2b). Vaccination with irra-
diated allogeneic cells alone or syngeneic tumor cells 
alone did not provide significant protection against a 
tumorigenic challenge with EL-4 cells [5]. The results 
of these studies also showed that the enhanced immu-
nity was not due simply to an allogeneic effect. In fact, 
co-administration (injection) into experimental mice 
of allogeneic cells together with irradiated autologous 
tumor cells (i.e., without fusion) did not protect them 
from a subsequent inoculation with autologous tumor 
cells, supporting the conclusion that, in order to achieve 
maximum anti-tumor protection, the tumor-associated 
antigen and the alloantigen needed to be on the same 
cell [5].
Irradiated semi-allogeneic tumor cell hybrids conferred 
protection against a subsequent tumorigenic inoculation 
of EL-4 cells; in contrast, control mice that were mock-
vaccinated with i.p.-injected phosphate-buffered saline 
(PBS) were killed by EL-4-derived lymphomas, which 
grew rapidly to a large size in the peritoneal cavity [6]. 
Focused microarray analyses performed on RNA purified 
from splenocytes of vaccinated (protected) mice revealed 
that expression of interferon (INF)-γ was upregulated 
while programmed cell death protein 1 (PD-1) expression 
was down-regulated compared to splenocyte RNA from 
control mice, suggesting that semi-allogeneic vaccines 
are able to activate cytotoxic T cells and interfere with, 
or even block, the tumor-mediated induction of immune 
tolerance, a key mechanism underlying the suppression 
of anti-tumor immunity in the immune competent host 
[6].
In an attempt to extend this immunotherapy approach 
to brain tumors, we tested semi-allogeneic vaccines in a 
mouse model of GBM. The mouse glioma 261 (GL261) 
was originally established by intracranial injection of 
3-methylcholantrene into C57BL/6 mice (H-2b haplo-
type), and serially passaged intracranially or subcuta-
neously as tissue tumor pieces in syngeneic mice [7]. 
Subsequently, GL261-derived cell cultures were estab-
lished to perform biological and immunological studies 
with the objective of investigating new treatment modali-
ties for GBM [8]. This research team also reported that 
subcutaneous (s.c.) vaccination with irradiated GL261 
cells was partially effective in a preventing the engraft-
ment of GL261-derived brain tumors, but totally ineffec-
tive in a therapeutic setting, i.e., when administered on 




GL261 cells were a generous gift from Dr. Michael R. 
Olin (University of Minnesota), and were tested and 
found free of adventitious agents, before being injected 
into mice. GL261 cells (H-2b haplotype) were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM, Inv-
itrogen), added with 10  % of fetal bovine serum (FBS, 
Atlanta Biologicals). We also tested the resistance of 
these cells in medium containing various concentra-
tions of the neomycin analog Geneticin (G418), and 
found that a medium containing 200  µg/mL of G418 
could kill GL261 within 2  weeks. Our stock of GL 
261 cells also expresses a transfected firefly luciferase 
gene, which allow us to monitor tumor engraftment by 
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bioluminescence imaging technology (see below). RAG 
cells were purchased from the American Type Culture 
Collection (ATCC), tested and found free of adventitious 
agents, before being injected into mice. RAG cells were 
cultured in DMEM added with 10 % FBS. RAG cells are 
deficient in the X-linked hypoxanthine-guanine phos-
phoribosyl transferase gene (HGPRT−). They are a non-
reverting, 8-azaguanine-resistant clone of the Renal-2a 
cell line, originally derived from a kidney adenocarci-
noma of BALB/c origin (H-2d haplotype); therefore, they 
are killed in culture media containing a supplement of 
hypoxanthine, aminopterin, and thymidine (HAT, Inv-
itrogen). We have previously confirmed that RAG cells 
are non-reverting, 8-azaguanine-resistant, and HAT-
sensitive [5, 6]. Neomycin-resistant RAG cells were gen-
erated by DNA-mediated gene transfer of the pRSV-neo 
plasmid (RAG-neo), as previously described [9]. RAG-
neo cells can grow in medium containing >400 µg/mL of 
G418. To generate semi-allogeneic somatic cell hybrids, 
single-cell suspensions of GL261 and RAG-neo cells were 
mixed at a 3:1 ratio in serum-free DMEM containing 
50 μM sodium dodecyl sulfate (SDS) and centrifuged at 
300×g for 5 min (min) at room temperature. The mixed 
cell pellet was then slowly suspended in 1 mL 50 % poly-
ethylene glycol (PEG)-1450 (cell-culture grade from the 
ATCC and diluted in serum-free DMEM) over a 1  min 
period while gently stirring. The cell suspension was then 
slowly diluted over a 2  min period with DMEM sup-
plemented with 10  % FBS. After centrifuging at 300xg 
for 5  min, fused cells were plated in selective medium 
(DMEM +  10  % FBS, containing 400  µg/mL G418 and 
HAT supplement). Under these culture conditions only 
RAG x GL261 semi-allogeneic somatic cell hybrids can 
survive, since RAG-neo cells are killed by aminopterin 
and GL261 cells are killed by G418.
Fluorescence‑activated cell sorting (FACS)
Drug-resistant cultures were expanded and tested by 
FACS for co-expression of MHC surface antigens using 
phycoerythrin (PE)-labeled, H-2Kb-specific monoclonal 
antibody (MAb) AF6-88.5 (BD Bioscience cat.# 553570), 
and allophycocyanin (APC)-labeled, H-2Kd-specific MAb 
SF1.1 (eBioscience cat.# 17-5957-82).
Animals
Mouse studies were reviewed and approved by the Insti-
tutional Animal Care and Use Committee (IACUC) 
and were conducted in accordance with all applicable 
national and institutional guidelines for the care and use 
of animals. Ten to twelve week-old C57BL/6 male mice 
(Jackson Laboratories) were anesthetized by i.p. injection 
of Ketamine (JHP Pharmaceuticals—90  mg/per kg) and 
Xylazine (Lloyd Laboratories—10 mg/kg), and positioned 
in a Kopf stereotaxic frame for intracranial injection 
into the striatum (2.2  mm medio-lateral, 0.2  mm ante-
rior-posterior, and 3  mm dorso-ventral). Injection into 
the right cerebral hemisphere of GL261 cells suspended 
in PBS (2  ×  104/mouse) was performed using a 5  μL 
Hamilton micro-syringe under mechanical control to 
avoid brain injuries during the procedure. Three days 
after tumor inoculation, treated mice were injected s.c. 
with lethally irradiated [30 Gray (Gy)] GL261xRAG-neo 
hybrids (106 cells per mouse) in 0.5 mL PBS, and control 
mice were injected s.c. with 0.5  mL PBS alone (mock-
vaccination). Mice were checked daily until the end of 
the experiment. Mice were euthanized as soon as they 
looked sick. Length of animal survival was measured by 
means of Kaplan–Meier graphs. Data from the animal 
experiments were analyzed using GraphPad Prism soft-
ware program (GraphPad Software Inc., La Jolla, CA, 
USA), with p  <  0.05 indicating statistical significance. 
Approximately 120 mice were tested in these experi-
ments, including mice used in preliminary studies aimed 
at optimizing the surgical procedures and determining 
the timing of vaccine administration. Less than 5  % of 
mice receiving intracranial inoculation of GL261 cells 
died within 48 h after surgery; these mice were excluded 
from the survival analyses.
Bioluminescence Imaging (BLI)
For BLI studies, luciferase activity was monitored 
using an Ivis 200 Spectrum Instrument (Perkin Elmer, 
Waltham, MA). Two and four days post-implantation 
of GL261 cells in the brain, mice were anesthetized in a 
chamber by inhalation of isoflurane (Florane, Baxter) at 
2–3 % in oxygen for the duration of the imaging session, 
and injected i.p. with 150 μL (150 mg/kg) of the biolumi-
nescent substrate ReadyJect D-Luciferin (PerkinElmer). 
Up to three mice were placed within the BLI chamber 
and imaged until measurable luciferase activity could 
be recorded. Serial images were obtained at 1, 4, 7, and 
10 min after i.p. injection of luciferin. Mice were imaged 
using the following parameters: field of view C, expo-
sure time 60 s, medium binning and F/Stop:1. Luciferase 
activity was calculated using Living Image Software (Per-
kin Elmer).
Pathology and immunohistochemistry
At time of sacrifice, mouse brains were removed and 
fixed for 24 h in 4 % paraformaldehyde in PBS. After fixa-
tion, brains were immersed in 30 % sucrose for cryosec-
tioning; sections were 5–30  μm-thick depending on the 
study. For morphological analysis, sections were stained 
with Hematoxylin and Eosin (H&E). Tumor volumes (in 
mm3) were estimated using image analysis (NIH Image 
software ImageJ 1.37v).
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For immunohistochemical studies, tissue sections were 
placed into wells containing 0.5  mL of Tris-buffered 
saline (TBS) and incubated in blocking buffer (TBS + 5 % 
FBS) for 1  h at room temperature. Primary antibodies 
diluted in blocking buffer were applied for 24 h at 4  °C. 
Primary antibodies used were: microglia-specific anti-
Iba1 (1:500; Wako cat.# 019-19741); anti-Ki-67 (1:100 
abcam cat.# ab16667); anti-CD3 (1:100 abcam cat.# 
ab5690); anti-CD4 (1:100 abcam cat.# ab25475); anti-
CD8 (1:100 abcam cat.# 22378). After the first incuba-
tion, sections were washed in TBS three times for 5 min 
and incubated for 60  min with secondary antibody 
(VECTSTAIN ABC Kit), followed by development using 
3,3′-diaminobenzidine (DAB) horseradish peroxidase 
(HRP) substrate (Vector Laboratories). Control sections 
were processed in identical fashion, except that the pri-
mary antibodies were omitted.
Results
Single-cell suspensions of GL261 and RAG-neo cul-
tures were fused using PEG 1450 and semi-allogeneic 
somatic cell hybrids were selected in DMEM  +  10  % 
FBS, containing 400 µg/mL G418 and HAT supplement. 
HAT-resistant and neomycin-resistant cell colonies 
became visible after 2–3  weeks; drug-resistant cultures 
were expanded and tested by FACS for expression of 
cell surface antigens derived from each parental cell. As 
expected, semi-allogeneic somatic cell hybrids expressed 
both H-2Kb (GL261) and H-2Kd (RAG-neo) MHC anti-
gens (Fig. 1).
We wanted to establish how soon GL261-derived 
tumors were detectable after intracranial injection of 
2  ×  104 GL261 cells per mouse. GL261 cells express 
a transfected gene coding for the firefly luciferase, 
which allows us to monitor tumor engraftment by 
bioluminescence imaging (BLI). Eight mice were imaged 
2 days post-implantation of GL261 cells and six of them 
(75  %) showed measurable luciferase activity within the 
brain, demonstrating the presence of metabolically active 
tumor cells. Figure 2a shows six of the eight mice imaged 
2 days post-implantation of GL261 cells, including mice 
#1 and #5 which appeared to be negative. On day four 
post-implantation, both of these mice showed luciferase 
activity within the right hemisphere of the brain, dem-
onstrating that the implanted GL261 cells, although not 
visible 2  days after inoculation in these mice, became 
detectable later because they grew over time (Fig. 2b).
In order to test GL261xRAG-neo hybrids as therapeu-
tic vaccines against GL261-derived glioma, 10  week-old 
C57BL/6 mice were administered under anesthesia an 
intracranial injection of 2 ×  104 GL261 cells per mouse 
and after 3 days mice in the experimental group received 
a s.c. injection of irradiated GL261xRAG-neo hybrids 
(106 cells per mouse) in PBS, and control mice were 
injected s.c. with PBS alone. We observed a significant 
longer survival in mice receiving the vaccine compared 
to control mice (Fig. 3a–c; p = 0.0027, p = 0.0466, and 
p  =  0.0258, respectively). The longest-surviving vacci-
nated mice from experiments shown in Fig.  3b, c were 
imaged by BLI at 99 and 93  days post-implantation 
of GL261 cells, respectively, and compared to tumor-
bearing mice as positive controls (Fig.  4). We observed 
no bioluminescence in the brain of the vaccinated mice 
compared to the control mice, which exhibited a strong 
positive signal, suggesting that the longest-surviving vac-
cinated mice were disease-free. The BLI-negative mouse 
shown in Fig. 4a had previously shown strong brain bio-
luminescence 2  days post-implantation of GL261 cells 
(mouse #2 in Fig.  2a) and was sacrificed 128  days post-
implantation to collect spleen and cervical lymph nodes 
Fig. 1 Cell surface staining of parental (GL261 and RAG) cells and semi‑allogeneic somatic cell hybrids (GL261xRAG). Single‑cell suspensions of 
each cell line were incubated with PE‑labeled, H‑2Kb‑specific MAb AF6‑88.5, and APC‑labeled, H‑2Kd‑specific MAb SF1‑1.1. Cell surface expressions 
of H‑2Kb and H‑2Kd antigens were measured by flow‑cytometry. Dot-plots show that GL261 cells only express the H‑2Kb antigen, RAG cells only 
express the H‑2Kd antigen, while GL261xRAG cells express both antigens
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(no tumor was observed in the brain). The BLI-negative 
mouse shown in Fig.  4b was sacrificed at day 105 post-
implantation to collect spleen and cervical lymph nodes. 
The results of these animal experiments are consistent 
with the estimate that 5-10 % of mice receiving a single 
vaccine administration became long-term survivors and 
appeared to be disease-free (and possibly cured) by BLI.
Brain tissue from mock-vaccinated mice (PBS alone) 
and two vaccinated mice sacrificed 86 days post-implan-
tation of GL261 cells (from survival experiment shown 
in Fig.  3a) were processed for histological examination 
and sections prepared for immunohistochemical stain-
ing, using as primary antibody a rabbit polyclonal anti-
serum specific for “ionized calcium binding adaptor 
molecule 1” (Iba1), a well-known marker for activated 
microglia (Fig. 5). We observed that microglia cells were 
less numerous within and around the tumor of mock-
vaccinated mice (Fig.  5a, b), compared to vaccinated 
mice (Fig.  5c–f). Activated microglia appeared to form 
a fence along the perimeter of the tumor cells (Fig.  5e). 
Fig. 2 Bioluminescence Imaging (BLI). All mice received an intracranial injection of 2 × 104 GL261 cells/mouse. For BLI, mice were anesthetized in 
a chamber containing a mixture of isoflurane (Florane, Baxter) and injected i.p. with 150 μL of the bioluminescent substrate ReadyJect d‑Luciferin. 
Mice were placed within the chamber of a Xenogen IVIS 200 Bioluminescence and Fluorescence Imaging System for up to 10 min and sets of serial 
images obtained. Eight mice were imaged 2 days post‑implantation of GL261 cells and six of them (75 %) showed measurable luciferase signal 
within the brain. a shows six of the eight imaged mice, including mice #1 and #5 which showed no signal. On day four post‑implantation, both 
mice #1 and #5 showed a positive signal within the brain (b)
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We also used antibodies specific for CD3, CD4, and CD8 
and observed lymphocytic infiltrates; in contrast to what 
observed with microglia, there were no obvious differ-
ences in tumor sections from vaccinated mice compared 
to tumor sections from mock-vaccinated mice (data not 
shown). Brain sections were also stained with anti-Ki67 
rabbit monoclonal SP6 (abcam, Cambridge, MA, USA) to 
investigate whether there were differences in the growth 
fraction of tumors from vaccinated mice compared to 
tumors from mock-vaccinated mice. We observed that 
the intensity and prevalence of Ki67-positive cells was 
comparable between the two groups and that in large 
tumors Ki67-positive cells were especially numerous at 
the edge of the tumor (data not shown).
Because of the significantly longer survival of vac-
cinated mice compared to mock-vaccinated ones, we 
attempted to quantify the difference in tumor volume 
between the two groups. Fourteen mice were inoculated 
with 2 ×  104 GL261 cells/mouse injected into the right 
hemisphere and after 3 days seven of them were injected 
s.c. with lethally irradiated (30  Gy) GL261xRAG-neo 
hybrids (106 cells per mouse). As soon as any mock-vacci-
nated mouse showed signs of stress or discomfort, it was 
sacrificed together with a randomly picked mouse from 
the vaccinated group and the brains processed for com-
parison of each pair. Figure 6a shows low-magnification 
Fig. 3 Survival graphs. a–c show Kaplan–Meier survival graphs of vac‑
cinated (treated) vs. mock‑vaccinated (control) mice. Three days after 
intracranial injection of 2 × 104 GL261 cells, control mice were mock‑
vaccinated s.c. with 0.5 mL PBS (blue graphs), while treated mice were 
vaccinated with lethally irradiated GL261xRAG‑neo hybrids (106 cells/
mouse) in 0.5 mL PBS (red graphs). Overall survival of vaccinated mice 
was significantly longer (p = 0.0027, p = 0.0466, and p = 0.0258, 
respectively)
Fig. 4 BLI of long‑term surviving mice. The vaccinated mouse shown 
on the left in figure a underwent BLI at 99 days post‑engraftment 
of GL261 cells; two control tumor‑bearing mice are shown at the 
center and right. The vaccinated mouse shown on the right of figure b 
underwent BLI at 93 days post‑engraftment with 2 × 104 GL261 cells; 
two control tumor‑bearing mice are shown at the center and left. Both 
vaccinated, long‑term surviving mice appeared to be disease‑free
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sections of the brain from the first three pairs and dem-
onstrate the striking difference in tumor size between 
the two groups at each time point. Comparison of tumor 
volumes based on serial sections of the brain from seven 
pairs of vaccinated and mock-vaccinated mice are shown 
in Fig.  6b, c. Tumor volumes were significantly smaller 
in vaccinated mice compared to mock-vaccinated mice 
(p < 0.0031).
Discussion
We report on the efficacy of a therapeutic cancer vaccine 
in mice inoculated with a lethal dose of GL261 glioma 
cells in the right hemisphere of the brain. Overall sur-
vival of vaccinated mice was significantly longer com-
pared to mock-vaccinated mice. Tumor volume in the 
brain of vaccinated mice was on average five to ten-fold 
smaller compared to mock-vaccinated mice. The sig-
nificant differences in tumor size and overall survival 
between vaccinated and mock-vaccinated mice resulted 
from a single s.c. injection of irradiated vaccine. It must 
be noted that subcutaneous vaccination with irradiated 
GL261 cells alone was partially effective in a preventive 
setting, but totally ineffective in a therapeutic setting, 
i.e., when administered on the day of intracranial tumor 
inoculation or 3 days thereafter [8]. Our results show that 
irradiated semi-allogeneic vaccines are effective in a ther-
apeutic setting.
In vaccinated mice, conspicuous microglia infiltrates 
were observed in tumor tissue sections and activated 
microglia appeared to form a fence along the perimeter 
of the tumor cells. Although these observations suggest 
an anti-GBM role for microglia infiltrates in vaccinated 
Fig. 5 Immunoperoxidase staining of microglia in brain sections from mock‑vaccinated and vaccinated mice. a The large tumor from a mock‑vac‑
cinated mouse occupies the central, lower and right areas in this image. Uninvolved brain is in the upper left quadrant of the image. Brown staining 
marks microglia in the surrounding brain and in the tumor. The border of the tumor with the surrounding brain is distinct but ragged (magnification 
×20). b This photomicrograph from the same mock‑vaccinated mouse shows the interface of tumor and adjacent brain. Staining for microglia is 
present in both. Tumor cells are hyperchromatic and atypical mitoses are present. A thin rim of microglia staining adjacent to tumor cells is visible 
(magnification ×100). c This photomicrograph shows a much smaller tumor in a vaccinated mouse. Microglia cells are intermingled within the 
tumor, attached to tumor cells, and are more numerous in surrounding brain. Microglia cells are also more numerous around tumor cells in vac‑
cinated mice compared to mock‑vaccinated ones (magnification ×40). d In this photomicrograph from the same vaccinated mouse, numerous 
microglia cells surround glioblastoma cells, distinguished by their nuclear atypia, pleomorphism, nucleomegaly and nucleoli. Microglia have much 
smaller nuclei and their cytoplasm is marked by the immunoperoxidase stain (magnification ×200). e In a different vaccinated mouse, microglia 
surround tumor cells, which are very large and have nucleomegaly with multiple nucleoli. Stained microglia cells are located on the perimeter of 
the malignant cells (magnification ×400). f This low‑power image of a small tumor from a vaccinated mouse shows the concentration of staining 
within the tumor and the large number of activated microglia in the surrounding neuropil (magnification ×20)
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mice, the balance of published evidence suggests that 
glioma-infiltrating macrophages favor tumor growth 
and infiltration into normal brain [10–12]. Although 
we did not observe clear differences in T cell infiltrates 
between vaccinated and mock-vaccinated mice, this does 
not imply that T cells do not play an important role in 
the anti-tumor response. Studies involving knock-out 
mice missing specific T-cell or macrophage cell lineages 
together with in  vitro studies are presently being con-
ducted to properly address this important issue. Addi-
tional immunohistochemical studies involving vaccinated 
and mock-vaccinated mice sacrificed at regular intervals 
will also be informative and help us understand the role 
of cell types responsible for the anti-tumor effects.
We reported on the use of semi-allogeneic vaccines 
as stimulators of HIV-envelope-specific cytotoxic T 
lymphocytes (CTL) and we proposed that semi-alloge-
neic cell hybrids functionally mimic antigen-presenting 
cells (APC) by concomitantly stimulating alloantigen-
specific T helper cells via allogeneic MHC, and antigen-
specific CTL precursors via antigen presentation through 
self-MHC [13]. We also proposed that the Th-1 cytokine 
response, induced through alloantigen-specific help, 
activates more efficiently antigen-specific CTL and that 
the cytokine-rich microenvironment of allograft rejec-
tion is crucial to attracting dendritic APC [5].Taken 
together, the results of these previous studies suggest 
that the semi-allogeneic platform for therapeutic cancer 
vaccines is essentially made of three components: (1) A 
“self” component, represented by the host-derived MHC 
haplotype (e.g., H-2b) expressed by the tumor cells; (2) an 
“allo” (non-self ) component represented by a different 
Fig. 6 Comparison of tumor size in brain sections from vaccinated and mock‑vaccinated mice. Animals from the two groups were sacrificed in 
pairs when any control mouse showed signs of discomfort. a shows corresponding sections of the brain (stained by H&E) from three pairs of mice 
for comparison. Tumors from mock‑vaccinated mice (i, iii, v) occupied most of the right hemisphere. In contrast, tumors from vaccinated mice (ii, 
iv, vi) were much smaller. b shows the bar graph of tumor volumes for each of the seven pairs of mice. c shows the bar graph of the cumulative 
data; tumor volumes were significantly smaller in vaccinated mice compared to mock‑vaccinated mice (p < 0.0031). Tumor volumes (in mm3) were 
estimated using image analysis (NIH Image software ImageJ 1.37v)
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cell line (e.g., RAG), that has a different MHC (H-2d) hap-
lotype; and (3) an “antigenic” component which is spe-
cific for the tumor (e.g., GL261). It should be possible to 
extend this immunotherapy approach to human subjects 
with GBM and test it through properly designed clini-
cal studies. By fusing RAG-like human cells [9, 14] with 
single cell suspensions from each patient-derived GBM, 
the antigenic complexity and specificity of each tumor 
would be captured, resulting in a therapeutic vaccine that 
is representative of each patient’s GBM. Thus, the long-
term objective of this translational research effort is to 
test irradiated, semi-allogeneic vaccines as an adjuvant 
to standard of care for human subjects diagnosed with 
GBM.
Conclusions
The results of these animal studies persuaded the Office 
of Orphan Products Development of the Food and Drug 
Administration to grant Orphan Drug Designation to the 
corresponding author for treatment of GBM with irradi-
ated, semi-allogeneic vaccines. Furthermore, these results 
are consistent with the recognition that immunotherapy 
has emerged as an important adjuvant in the therapeutic 
armamentarium of clinicians against GBM [15], and sup-
port the goal of translating our immunotherapy approach 
into clinical studies, with a special focus on Veterans with 
GBM, because of their significantly shorter survival com-
pared to non-VA patients with the same diagnosis [3].
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